SECTORAL ASSET MANAGEMENT INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 134 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.

Quarter-by-quarter ownership
SECTORAL ASSET MANAGEMENT INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$5,577,200
+10.9%
146,000
+4.7%
1.09%
+29.4%
Q2 2023$5,029,493
+12.2%
139,437
+18.8%
0.84%
-2.7%
Q1 2023$4,483,506
-42.7%
117,400
-14.6%
0.86%
-43.0%
Q4 2022$7,818,060
+43.9%
137,4000.0%1.51%
+41.4%
Q3 2022$5,433,000
-5.3%
137,400
+5.4%
1.07%
-7.4%
Q2 2022$5,738,000
+14.2%
130,400
+3.5%
1.16%
+29.6%
Q1 2022$5,025,000
+800.5%
126,000
+505.8%
0.89%
+1649.0%
Q2 2020$558,000
-98.4%
20,800
-99.0%
0.05%
-96.7%
Q4 2015$35,974,000
+0.3%
2,075,796
-22.3%
1.53%
-6.6%
Q3 2015$35,872,000
-54.3%
2,671,051
-23.2%
1.64%
-49.8%
Q2 2015$78,512,000
+47.5%
3,477,051
-6.7%
3.28%
+62.0%
Q1 2015$53,229,000
+48.1%
3,727,551
+0.1%
2.02%
+25.4%
Q4 2014$35,940,000
-13.4%
3,724,351
-18.3%
1.61%
-7.7%
Q3 2014$41,487,000
-4.3%
4,558,982
+3.9%
1.75%
-5.0%
Q2 2014$43,370,000
-36.3%
4,389,682
-18.0%
1.84%
-34.3%
Q1 2014$68,041,000
-3.5%
5,355,488
+13.9%
2.80%
-7.9%
Q4 2013$70,473,000
+45.5%
4,701,362
+7.2%
3.04%
+30.4%
Q3 2013$48,425,000
+86.8%
4,386,362
+34.5%
2.33%
+203.8%
Q2 2013$25,925,0003,260,9620.77%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2014
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders